Class / Patent application number | Description | Number of patent applications / Date published |
514200600 | Streptococcus | 54 |
20100261659 | SECRETED FRIZZLED RELATED PROTEIN 3 FOR USE IN THE INHIBITION OF SCARRING - Provided is secreted Frizzled Related Protein 3 (sFRP3), or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. The scarring may be associated with the healing of a wound, or with a fibrotic disorder. The scarring may be associated with surgical wounds. The scarring may be scarring of the skin. The medicament may be a topical medicament, and may be suitable for local injection. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of sFRP3, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition. | 10-14-2010 |
20110077207 | METHOD FOR TREATING INFLAMMATION - A method for treating down-regulating IL-19 or mda7 by administering the soluble IL-20RA/IL-20R heterodimeric receptor. | 03-31-2011 |
20110112037 | CRYSTAL STRUCTURE - The invention provides a method of predicting a three dimensional structural representation of a target protein of unknown structure, or part thereof, comprising: providing the coordinates of the turkey β1-AR structure listed in Table A, Table B, Table C or Table D, optionally varied by a root mean square deviation of residue backbone atoms of not more than 1.235 A, or selected coordinates thereof; and predicting the three-dimensional structural representation of the target protein, or part thereof, by modelling the structural representation on all or the selected coordinates of the turkey β1-AR. The invention also provides the use of the turkey β1-AR coordinates to select or design one or more binding partners of β1-AR. | 05-12-2011 |
20120178701 | Melanocortin Receptor-Specific Peptides - Melanocortin receptor-specific cyclic peptides of the formula | 07-12-2012 |
20130023483 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY - Specific template-fixed β-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are α-amino acid residues connected from the carbonyl (C═O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these β-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells. | 01-24-2013 |
20130079290 | S1P ANTAGONISTS AS ADJUNCT OCULAR HYPOTENSIVES - The invention provides compositions and methods for further reducing IOP in a subject who has already achieved maximal IOP reduction using known IOP lowering agents. The activity of an ocular hypotensive treatment regimen may be increased by adding an S1P antagonist to prevent S1P mediated reversal as a result of decreased aqueous humor outflow. | 03-28-2013 |
20140142046 | NOVEL WNT COMPOSITIONS AND THERAPEUTIC USES OF SUCH COMPOSITIONS - The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth. | 05-22-2014 |
20140243277 | Water Soluble Membrane Proteins and Methods for the Preparation and Use Thereof - The present invention is directed to water-soluble membrane proteins, methods for the preparation thereof and methods of use thereof. | 08-28-2014 |
20140329761 | PREVENTION AND TREATMENT OF ACUTE INFLAMMATORY CONDITIONS - The present invention relates generally to methods for the prevention and treatment of acute inflammatory conditions in individuals using an agonist of the complement C3a receptor. | 11-06-2014 |
20150025021 | DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR MODULATORS - The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor. | 01-22-2015 |
20150105329 | Methods and Pharmaceutical Compositions for Prevention or Treatment of Ischemia Related Organ Damage - The present invention relates to methods and compositions for the prevention or treatment of ischemia related organ damage. | 04-16-2015 |
20150290286 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DYSFUNCTION ASSOCIATED WITH AGING - The present invention relates to an APJ receptor agonist or an apelinomimetic for use in the treatment or the prevention of a dysfunction associated with aging. | 10-15-2015 |
20100261638 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY - The present invention provides actagardine, actagradine B and deoxy actagardine B derivatives of formula (I), | 10-14-2010 |
20100286028 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 11-11-2010 |
20100286029 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 11-11-2010 |
20100323950 | USE OF BETA-MELANOTROPIN AS A THERAPEUTIC AGENT, EG FOR THE TREATMENT OF AIDS OR ALZHEIMER - The present invention is directed to the use of the peptide compound Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 12-23-2010 |
20100331241 | Bacteriocins and Novel Bacterial Strains - Novel bacteriocins and/or the novel lactic acid-producing strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry. | 12-30-2010 |
20110105385 | Antibacterial lactobacillus GG peptides and methods of use - The present invention provides antibacterial peptides isolated from | 05-05-2011 |
20110201546 | METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described. | 08-18-2011 |
20110207657 | Selectively Targeted Antimicrobial Peptides and the Use Thereof - The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., | 08-25-2011 |
20110245152 | ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE - The present invention relates to a novel | 10-06-2011 |
20110269670 | CARBOHYDRATE BINDING MOLECULES - The present invention provides compounds, compositions, medicaments and methods comprising or using carbohydrate binding molecules. More specifically, the invention provides a means of treating diseases and/or conditions caused or contributed to by pathogens, particularly microbial pathogens and methods of screening, identifying, detecting tagging and/or labelling carbohydrates. | 11-03-2011 |
20120058935 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREFORE - The invention features antimicrobial compositions comprising β-amyloid peptides, oligomers, and analogs thereof, and methods of using them for the prevention or treatment of an infection. | 03-08-2012 |
20120071398 | ANTI-MICROBIAL PEPTIDES - The present invention relates to peptides comprising amino acids according to Formula I | 03-22-2012 |
20120108498 | STRUCTURAL AND MECHANISTIC BASIS FOR NOVEL COMPOUND BIOSYNTHESIS USING THE 4-ELECTRON HEXOSE OXIDASE - A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections. | 05-03-2012 |
20120115774 | ANTIMICROBIAL CATIONIC LIPO-BETA-PEPTIDES - In some aspects, the present invention provides ultrashort lipopeptides which feature β-amino acids or β-peptides and demonstrate antimicrobial activity. Accordingly, some aspects of the present invention provide lipopeptide compositions and methods of making and using the compositions as antimicrobial agents. | 05-10-2012 |
20120172289 | MULTIFUNCTIONAL GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES FOR FLUORESCENT IMAGING AND PHOTOACTIVE ANTIMICROBIAL THERAPY - The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection. | 07-05-2012 |
20120316103 | CYCLIC ANTIMICROBIAL PEPTIDES - The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections. | 12-13-2012 |
20130102523 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE - A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included. | 04-25-2013 |
20130150286 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS - The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection. | 06-13-2013 |
20130172237 | METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described. | 07-04-2013 |
20130184200 | Immunogenic Polypeptides and Monoclonal Antibodies - Provided herein are compositions and methods for eliciting an immune response against | 07-18-2013 |
20130184201 | Cyclodepsipeptides with Antineoplastic Activity and Methods of Using to Inhibit Cancer and Microbial Growth - The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host. | 07-18-2013 |
20130217619 | LINEAR PEPTIDE ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 08-22-2013 |
20130231276 | Combination Of An Aminoacyl-tRNA Synthetase Inhibitor With A Further Antibacterial Agent For Attenuating Multiple Drug Resistance - Bacterial multidrug resistance is attenuated in a subject by administering an aminoacyl-tRNA synthetase inhibitor and an antibacterial agent to the subject, wherein the aminoacyl-tRNA synthetase inhibitor is distinct from the antibacterial agent. | 09-05-2013 |
20130274174 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE - A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included. | 10-17-2013 |
20130281360 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS - Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided. | 10-24-2013 |
20130345120 | PEPTIDE DEFORMYLASE INHIBITORS - The present invention relates to a compound of Formula (I): | 12-26-2013 |
20140128314 | Bacteriocin Derived from Lactobacillus Rhamnosus - Provided is a bacteriocin that is capable of being easily mass-produced, has high antimicrobial activity even at low concentration, has a wide antimicrobial spectrum, and is less likely to produce resistant microorganisms. The bacteriocin has the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING, or has the same amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING except that one or several amino acids are deleted, substituted, inserted and/or added, wherein the amino acid sequence provides antimicrobial activity and the isoelectric point is not less than 12. | 05-08-2014 |
20140142028 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 05-22-2014 |
20140142029 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 05-22-2014 |
20140155319 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif. | 06-05-2014 |
20140179594 | STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR TREATMENT OF GRAM POSITIVE BACTERIA IN COMPANION ANIMALS AND LIVESTOCK - The present invention provides methods for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria in companion animals and livestock, including | 06-26-2014 |
20140194345 | NOVEL DEPSIPEPTIDE AND USES THEREOF - The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders. | 07-10-2014 |
20140206601 | Methods and Pharmaceutical Compositions for the Treatment of Respiratory Tract Infections - The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection. | 07-24-2014 |
20140213506 | THYMOSIN ALPHA PEPTIDE FOR PREVENTING, REDUCING THE SEVERITY OF, AND TREATING INFECTION - The present invention provides methods for preventing, treating, or reducing the severity of infection, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen, so as to prime or enhance a patient's immune response for pathogen exposure. In certain embodiments, the alpha thymosin regimen is scheduled or timed with respect to potential or expected pathogen exposures. The regimen of alpha thymosin peptide as described herein provides the patient with a more robust immune response to pathogen exposure, including higher antibody titers and/or a more rapid antibody response. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide helps to protect the patient from, or reduce the severity of nosocomial infection or illness. | 07-31-2014 |
20140303071 | CYCLIC ANTIMICROBIAL PEPTIDES - The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections. | 10-09-2014 |
20140349918 | DERIVATIVES OF XANTHONE COMPOUNDS - The present invention relates to xanthone analogs. Such compounds may be used in the treatment of bacterial infections. | 11-27-2014 |
20150011464 | ANTIBACTERIAL POLYPEPTIDES AND USE THEREOF - The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed. | 01-08-2015 |
20150018268 | MULTIVALENT SYNTHETIC COMPOUNDS AS ANTIBIOTIC TREATMENT - The present invention relates to the use of a multivalent synthetic compound, which is significantly more resistant to at least one protease than a standard peptide bond, for preparing a medication, and methods of use for the treatment of diseases, e.g., due to bacterial and/or microbial growth. | 01-15-2015 |
20150018269 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND USE THEREOF - The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases. | 01-15-2015 |
20150045286 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS - Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided. | 02-12-2015 |
20150072922 | RNASE 7 ANTIMICROBIAL PEPTIDES - Described herein are compounds and compositions comprising antimicrobial peptides and methods for their use. | 03-12-2015 |
20150111813 | BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN - The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant | 04-23-2015 |
20150148286 | POTENTIATION OF ANTIBIOTIC TREATMENT WITH A PROTEIN-LIPID COMPLEX - Provided are compositions and methods for potentiating the effect of antibiotics. The compositions comprise a non-covalent complex of alpha-lactalbumin and fatty acid. The fatty acids are cis, unsaturated, C14 to C20 fatty acids. The complex and antibiotic can be administered to an individual together or separately. The antibiotic may be one to which resistance has developed. | 05-28-2015 |
20160031940 | WATER BUFFALO DERIVED PEPTIDE ANTIBIOTIC THERAPIES - The present disclosure relates to antimicrobial agents and methods of using such agents. The disclosure includes antimicrobial agents having broad spectrum antimicrobial activity, nucleic acids and amino acid sequences encoding such antimicrobial agents, as well as methods of using the antimicrobial agents. The antimicrobial agents of the disclosure may be used to reduce survival of a microbe, as an antimicrobial therapeutic, in microbial treatment protocols, and in research, as well as other uses related to reducing microbe survival. In addition, the disclosure also includes compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial agent. | 02-04-2016 |
20160031954 | WATER BUFFALO DERIVED DIMERIC PEPTIDE CONTAINING PROLINE FOR ANTIBIOTIC THERAPIES - The present disclosure relates to antimicrobial agents and methods of using such agents. The disclosure includes antimicrobial agents having broad spectrum antimicrobial activity, nucleic acids and amino acid sequences encoding such antimicrobial agents, as well as methods of using the antimicrobial agents. The antimicrobial agents of the disclosure may be used to reduce survival of a microbe, as an antimicrobial therapeutic, in microbial treatment protocols, and in research, as well as other uses related to reducing microbe survival. In addition, the disclosure also includes compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial agent. | 02-04-2016 |
20160052964 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS - Certain embodiments are directed to compositions and methods of inhibiting a pathogenic bacterial infection involving ADAM10, specifically a method for treating pore-forming toxin-inducted pathology caused by exposure to | 02-25-2016 |
20160083427 | CYCLIC CATIONIC PEPTIDES WITH ANTIBMICROBIAL ACTIVITY - A series of cationic cyclic peptides, useful for the treatment of infectious diseases in both human and veterinary clinical/surgical environment are described herein. The peptides of the invention have a length of 15 to 21 amino acids, and show a sequence A-B-C-D-C′-B′-A′, wherein units A and A′ correspond to —NH | 03-24-2016 |
20160106689 | USE - The present invention relates to compositions comprising cysteamine or a derivative thereof for use in treating infections caused by yeasts or moulds. | 04-21-2016 |
20160113921 | COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS - The present invention provides a combination of at least one oxazolidinone-quinolone hybrid with at least one further antibacterial compound and the use thereof as drug, especially for the treatment or prophylaxis of bacterial infections. | 04-28-2016 |
20160151453 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS | 06-02-2016 |
20160168203 | Cyclic Antimicrobial Peptides | 06-16-2016 |
20160194358 | LINEAR PEPTIDE ANTIBIOTCS | 07-07-2016 |
20160376320 | ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES - Disclosed herein are novel anti-microbial peptides with inhibitory activity against | 12-29-2016 |
20170232060 | ANTIMICROBIAL 4-OXOQUINOLIZINES | 08-17-2017 |